Literature DB >> 25556309

Endocrine and metabolic changes affecting cardiovascular disease in dialysis patients.

Tetsuo Shoji1, Masanori Emoto2, Yoshiki Nishizawa2, Masaaki Inaba2.   

Abstract

Protein-energy wasting plays an important role in the increased risk of mortality from cardiovascular disease in people with end-stage renal disease. Because protein-energy wasting is a condition of imbalance between anabolism and catabolism, endocrine and metabolic alterations that regulate such balance should be the possible target of intervention. Subjects with end-stage renal disease exhibit various changes in thyroid function, gonadal hormones, adrenal androgen, glucose metabolism, dyslipidemia, fatty acid composition, cholesterol absorption, and vitamin D. In this article, we briefly review the association of these alterations with mortality and cardiovascular disease in hemodialysis patients. Although some of them may be the adaptive response to the catabolic condition, these observational data are useful for risk stratification of patients and also for providing new ideas for possible prevention.
Copyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25556309     DOI: 10.1053/j.jrn.2014.10.018

Source DB:  PubMed          Journal:  J Ren Nutr        ISSN: 1051-2276            Impact factor:   3.655


  2 in total

1.  Prognosis and risk factors for cardiac valve calcification in Chinese end-stage kidney disease patients on combination therapy with hemodialysis and hemodiafiltration.

Authors:  Jian-Qiong Xiong; Xue-Mei Chen; Chun-Ting Liang; Wen Guo; Bai-Li Wu; Xiao-Gang Du
Journal:  Ren Fail       Date:  2022-12       Impact factor: 2.606

2.  Linagliptin monotherapy compared with voglibose monotherapy in patients with type 2 diabetes undergoing hemodialysis: a 12-week randomized trial.

Authors:  Katsuhito Mori; Masanori Emoto; Tetsuo Shoji; Masaaki Inaba
Journal:  BMJ Open Diabetes Res Care       Date:  2016-07-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.